Exosome-Enhanced Sonodynamic Therapy in Cancer: Emerging Synergies and Modulation of the Tumor Microenvironment
Open Access
Abstract
The development of safer, more effective, and tumor-specific therapeutic strategies remains a major challenge in oncology. Conventional treatments such as chemotherapy and radiotherapy often cause severe side effects and are limited in their ability to target deep-seated or resistant tumors. In this context, sonodynamic therapy (SDT) has emerged as a promising, non-invasive option, harnessing low-intensity ultrasound to activate sonosensitizers deep within tissues and generate cytotoxic reactive oxygen species (ROS) that selectively induce cancer cell death. Interestingly, SDT can also be combined with other therapies to achieve synergistic effects. However, despite encouraging preclinical results, SDT clinical translation is hindered by the poor aqueous solubility, instability, and low tumor specificity of traditional sonosensitizers. To overcome these limitations, recent studies have focused on employing extracellular vesicles (EVs), especially exosomes, as natural, biomimetic nanocarriers for sonosensitizer delivery. EVs offer unique advantages, including high biocompatibility, low immunogenicity, and intrinsic tumor-targeting ability, which make them ideal platforms for improving the therapeutic precision of SDT. Although several delivery strategies have been proposed, a comprehensive and focused overview of approaches specifically designed to enhance SDT performance using EVs is currently lacking. This review summarizes recent advances in integrating EVs with SDT for cancer treatment. It discusses the mechanisms underlying SDT, the engineering strategies developed to enhance exosome functionality, and the synergistic effects achieved through this combination. Furthermore, this review emphasizes that EV-based SDT not only enhances tumor accumulation of the therapeutic nanoplatforms, but also actively remodels the tumor microenvironment by improving oxygen availability, reversing immunosuppressive conditions, and triggering durable antitumor responses. Finally, the review addresses the translational challenges and outlines the critical future directions required to advance this promising therapeutic approach toward clinical application.Keywords
Funding Information
- European Union’s Horizon 2020 Research and Innovation Program (964386)
- European Union’s Horizon 2020 Research and Innovation Program (101081529)
This publication has 167 references indexed in Scilit:
- Tumor‐Targeted Exosome‐Based Heavy Atom‐Free Nanosensitizers With Long‐Lived Excited States for Safe and Effective Sono‐Photodynamic Therapy of Solid TumorsAdvanced Healthcare Materials, 2025
- A Perspective on Ultrasound‐Triggered Production of Reactive Oxygen Species by Inorganic Nano/MicroparticlesAdvanced NanoBiomed Research, 2024
- Exosome‐Inhibiting Polymeric Sonosensitizer for Tumor‐Specific Sonodynamic ImmunotherapyAdvanced Materials, 2024
- Tumor Microenvironment‐Related Sonodynamic Therapy Mediates Tumor TherapyAdvanced Therapeutics, 2023
- Strategies to Reverse Hypoxic Tumor Microenvironment for Enhanced Sonodynamic TherapyAdvanced Healthcare Materials, 2023
- Emerging Sonodynamic Therapy‐Based Nanomedicines for Cancer ImmunotherapyAdvanced Science, 2022
- Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of GlioblastomaAdvanced Materials, 2022
- Design and Challenges of Sonodynamic Therapy System for Cancer Theranostics: From Equipment to SensitizersAdvanced Science, 2021
- Ultrasound‐Activated Oxygen and ROS Generation Nanosystem Systematically Modulates Tumor Microenvironment and Sensitizes Sonodynamic Therapy for Hypoxic Solid TumorsAdvanced Functional Materials, 2019
- ROS‐Responsive Blended Nanoparticles: Cascade‐Amplifying Synergistic Effects of Sonochemotherapy with On‐demand Boosted Drug Release During SDT ProcessAdvanced Healthcare Materials, 2019